<DOC>
	<DOCNO>NCT00069108</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety intermittent oral Xeloda , iv fluorouracil/leucovorin , combination intravenous Eloxatin ( oxaliplatin ) patient previously treat metastatic colorectal cancer . Patients randomize receive either 1 ) XELOX ( Xeloda 1000mg/m2 po bid day 1-15 + oxaliplatin ) 3 week cycle 2 ) FOLFOX-4 ( oxaliplatin + leucovorin + 5-FU 2 week cycle . The anticipated time study treatment disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patient &gt; =18 year age ; metastatic colorectal cancer ; &gt; =1 target lesion ; fail firstline chemotherapy 5fluorouracil irinotecan . previous treatment oxaliplatin ; progressive recurrent disease within 6 month completion firstline chemotherapy ; &gt; =1 previous chemotherapeutic agent systemic anticancer regimen metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>